TIDMMPH
RNS Number : 0751O
Mereo BioPharma Group plc
27 May 2020
Notice of Annual General Meeting
London and Redwood City, Calif., May 27, 2020 - Mereo BioPharma
Group plc (NASDAQ: MREO, AIM: MPH) "Mereo" or "the Company", a
clinical-stage biopharmaceutical company focused on oncology and
rare diseases, today announces, as per its 'Annual General Meeting'
announcement, released on May 22, 2020, that its Annual General
Meeting (AGM) is to be held on June 29, 2020 at 3:00 p.m. at 1
Cavendish Place, London W1G 0QF, United Kingdom. A copy of the
Notice of AGM is available on the Company's website:
www.mereobiopharma.com/news-and-events/press-releases/2020/notice-of-agm/notice-of-agm/
and the Notice of AGM (or a notification of the availability of the
Notice of AGM) will be posted to shareholders shortly, where
appropriate.
Due to COVID-19 and the current social distancing measures set
out by the Government, Mereo's AGM will be a closed meeting. As
iterated in the release on May 22, 2020, this means that ordinary
shareholders will not be allowed to attend the AGM in person and
any ordinary shareholder seeking to attend the AGM in person will
be refused entry.
Under the Companies Act 2006, the directors of a public company
are required to lay its annual accounts and reports before the
company in general meeting (an "accounts meeting") by no later than
the end of the period for the filing of those accounts and reports
with the Registrar of Companies. The period for filing the annual
accounts and reports is ordinarily six months from the accounting
reference date. There is a separate requirement under the Companies
Act 2006 for a public company to hold an AGM within the period of
six months from its accounting reference date.
Ordinarily the Company's AGM would also serve as its accounts
meeting. However, in response to the COVID-19 pandemic, Companies
House has allowed companies to apply for a three-month extension of
time to file their accounts. The Company has applied for, and been
granted, such an extension in respect of its annual accounts and
reports for the financial year ended December 31, 2019 (the "Annual
Accounts"). The Company is still aiming to announce and publish the
Annual Accounts by June 30, 2020, however the extension allows
until September 30, 2020, if required.
In light of this extension, the Company's accounts meeting may
now be held as a general meeting no later than September 30, 2020.
However, the Company is currently still required to hold its AGM by
June 30, 2020, hence the meeting going ahead as stated above. It is
noted that the Annual Accounts will not be able to be sent out to
shareholders in sufficient time ahead of the AGM and therefore will
not be laid before the AGM.
About Mereo BioPharma
Mereo BioPharma is a biopharmaceutical company focused on the
development and commercialization of innovative therapeutics that
aim to improve outcomes for patients with rare diseases. Mereo's
strategy is to selectively acquire product candidates for rare
diseases that have already received significant investment from
pharmaceutical and large biotechnology companies and that have
substantial preclinical, clinical and manufacturing data packages.
The Company also acquired two clinical stage oncology products as a
result of the merger with Oncomed Pharmaceuticals Inc. in 2019.
Mereo's lead rare disease product candidate, setrusumab, has
completed a Phase 2b dose-ranging study in adults with osteogenesis
imperfecta ("OI") and a pivotal Phase 3 study design in paediatrics
has been agreed with the FDA and EMA. Mereo's second lead product
candidate, alvelestat, is being investigated in a Phase 2
proof-of-concept clinical trial in patients with alpha-1
antitrypsin deficiency ("AATD"). Mereo's lead oncology product
candidate, etigilimab, an anti-TIGIT, has entered Phase 1b for a
range of solid tumor types and the second product candidate,
navicixizumab, has been licensed to Oncologie Inc. for up to $300M
in milestone payments. Following successful completion of Phase 2,
Mereo is seeking partnerships for it's two additional
clinical-stage product candidates; acumapimod for the treatment of
acute exacerbations of chronic obstructive pulmonary disease
("AECOPD"), leflutrozole for the treatment of hypogonadotropic
hypogonadism ("HH") in obese men. Mereo continues to evaluate
financing options through a combination of partnering and equity
offering alongside prioritisation of the product candidate
portfolio.
Additional Information
The person responsible for arranging the release of this
information on behalf of the Company is Charles Sermon, General
Counsel.
Forward-Looking Statements
This Announcement contains "forward-looking statements." All
statements other than statements of historical fact contained in
this Announcement are forward-looking statements within the meaning
of Section 27A of the United States Securities Act of 1933, as
amended (the "Securities Act"), and Section 21E of the United
States Securities Exchange Act of 1934, as amended (the "Exchange
Act"). Forward-looking statements usually relate to future events
and anticipated revenues, earnings, cash flows or other aspects of
our operations or operating results. Forward-looking statements are
often identified by the words "believe," "expect," "anticipate,"
"plan," "intend," "foresee," "should," "would," "could," "may,"
"estimate," "outlook" and similar expressions, including the
negative thereof. The absence of these words, however, does not
mean that the statements are not forward-looking. These
forward-looking statements are based on the Company's current
expectations, beliefs and assumptions concerning future
developments and business conditions and their potential effect on
the Company. While management believes that these forward-looking
statements are reasonable as and when made, there can be no
assurance that future developments affecting the Company will be
those that it anticipates.
All of the Company's forward-looking statements involve known
and unknown risks and uncertainties (some of which are significant
or beyond its control) and assumptions that could cause actual
results to differ materially from the Company's historical
experience and its present expectations or projections. The
foregoing factors and the other risks and uncertainties that affect
the Company's business, including those described in its Annual
Report on Form 20-F, Reports on Form 6-K and other documents filed
from time to time by the Company with the United States Securities
and Exchange Commission (the "SEC") and those described in other
documents the Company may publish from time to time should be
carefully considered. The Company wishes to caution you not to
place undue reliance on any forward-looking statements, which speak
only as of the date hereof. The Company undertakes no obligation to
publicly update or revise any of our forward-looking statements
after the date they are made, whether as a result of new
information, future events or otherwise, except to the extent
required by law.
Mereo BioPharma Contacts:
Mereo +44 (0)333 023 7300
Denise Scots-Knight, Chief Executive Officer
Cantor Fitzgerald Europe (Nominated Adviser
and Broker to Mereo ) +44 (0)20 7894 7000
Phil Davies
Will Goode
Burns McClellan (US Public Relations Adviser
to Mereo) +01 (0) 212 213 0006
Lisa Burns
Steve Klass
FTI Consulting (UK Public Relations Adviser
to Mereo ) +44 (0)20 3727 1000
Simon Conway
Ciara Martin
Investors investors@mereobiopharma.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NOAUBUKRRUUVURR
(END) Dow Jones Newswires
May 27, 2020 07:00 ET (11:00 GMT)
Mereo Biopharma (LSE:MPH)
過去 株価チャート
から 12 2024 まで 1 2025
Mereo Biopharma (LSE:MPH)
過去 株価チャート
から 1 2024 まで 1 2025
